Saudi Journal of Kidney Diseases and Transplantation

ORIGINAL ARTICLE
Year
: 2009  |  Volume : 20  |  Issue : 3  |  Page : 392--397

Spironolactone in chronic hemodialysis patients improves cardiac function


Shahram Taheri1, Mojhgan Mortazavi1, Shahrzad Shahidi1, Ali Pourmoghadas2, Mohammad Garakyaraghi2, Shiva Seirafian1, Afrooz Eshaghian3, Maryam Ghassami3 
1 Division of Nephrology, Department of Internal Medicine, Isfahan School of Medicine, Isfahan, Iran
2 Division of Cardiology, Department of Internal Medicine, Isfahan School of Medicine, Isfahan, Iran
3 Division of Students of Medicine, Department of Internal Medicine, Isfahan School of Medicine, Isfahan, Iran

Correspondence Address:
Shahram Taheri
Department of Internal Medicine, St. Al-Zahra Hospital, Soffeh Ave., Isfahan
Iran

We performed this study to assess whether low dose spironolactone could be admi­nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio­vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro­nic HD patients with moderate to severe heart failure and left ventricle ejection fraction :5 45%. In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spi­ronolactone after each dialysis session within six months, and the rest received a placebo. Echo­cardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study. Serum potassium was measured predialysis every 4 weeks. The mean ejection fraction increased signi­ficantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs. 0.83 ± 4.9, P= 0.046). The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs. 3 ± 7.97. 95%, P= 0.021). The incidence of hyperkalemia was not significantly increased in the study or controlled groups. In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia.


How to cite this article:
Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, Eshaghian A, Ghassami M. Spironolactone in chronic hemodialysis patients improves cardiac function.Saudi J Kidney Dis Transpl 2009;20:392-397


How to cite this URL:
Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, Eshaghian A, Ghassami M. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl [serial online] 2009 [cited 2019 Dec 8 ];20:392-397
Available from: http://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=3;spage=392;epage=397;aulast=Taheri;type=0